- Home
- NGNE vs MIY Comparison
NGNE vs MIY Comparison
Compare NGNE & MIY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- MIY
- Stock Information
- Founded
- NGNE 2003
- MIY 1992
- Country
- NGNE United States
- MIY United States
- Employees
- NGNE N/A
- MIY N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- MIY Investment Bankers/Brokers/Service
- Sector
- NGNE Health Care
- MIY Finance
- Exchange
- NGNE Nasdaq
- MIY Nasdaq
- Market Cap
- NGNE 325.3M
- MIY 312.2M
- IPO Year
- NGNE N/A
- MIY N/A
- Fundamental
- Price
- NGNE $22.72
- MIY $10.80
- Analyst Decision
- NGNE Strong Buy
- MIY
- Analyst Count
- NGNE 7
- MIY 0
- Target Price
- NGNE $41.86
- MIY N/A
- AVG Volume (30 Days)
- NGNE 216.3K
- MIY 56.8K
- Earning Date
- NGNE 08-08-2025
- MIY 01-01-0001
- Dividend Yield
- NGNE N/A
- MIY 3.98%
- EPS Growth
- NGNE N/A
- MIY N/A
- EPS
- NGNE N/A
- MIY N/A
- Revenue
- NGNE $925,000.00
- MIY N/A
- Revenue This Year
- NGNE N/A
- MIY N/A
- Revenue Next Year
- NGNE N/A
- MIY N/A
- P/E Ratio
- NGNE N/A
- MIY N/A
- Revenue Growth
- NGNE N/A
- MIY N/A
- 52 Week Low
- NGNE $6.88
- MIY $9.45
- 52 Week High
- NGNE $74.49
- MIY $11.70
- Technical
- Relative Strength Index (RSI)
- NGNE 60.64
- MIY 40.54
- Support Level
- NGNE $20.80
- MIY $10.62
- Resistance Level
- NGNE $23.88
- MIY $11.36
- Average True Range (ATR)
- NGNE 1.44
- MIY 0.12
- MACD
- NGNE 0.09
- MIY 0.00
- Stochastic Oscillator
- NGNE 72.83
- MIY 29.11
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.